Literature DB >> 7523045

Low level CD20 expression on T cell malignancies.

M J Warzynski1, D M Graham, R A Axtell, M H Zakem, R K Rotman.   

Abstract

Although initially thought to be a B lineage restricted antigen, low "density" or antibody binding capacity (ABC) CD20 has recently been detected on subset(s) of normal T lymphocytes (Hultin et al.: Cytometry 14:196-204, 1993). We report low ABC CD20 expression in three (two children, one adult) cases of T-acute lymphoblastic leukemia (T-ALL). CD20 and other pertinent antigens were detected using a direct dual color method with a Becton Dickinson FACScan flow cytometer and Simulset software. Only one cell population based on light scatter was noted in each case that immunophenotypically represented almost a pure population of malignant cells expressing T lymphocyte antigens (for example, CD7 98%, 92%, and 100%, respectively). A total of 95%, 87%, and 79% of the cells from the three cases expressed CD20 with an unusual low ABC compared to the customary "bright" CD20 expression on normal B lymphocytes. Other B lymphocyte associated antigens, such as CD19, CD22, Dr, and immunoglobulin light chains, were negative. Eleven other T lymphocytic malignancies from 1991 to 1993 were CD20 negative, including three other case of T-ALL (one adult and two children). One unusual case of intestinal small lymphocytic non-Hodgkin's lymphoma with a natural killer/T lymphocytic immunophenotype not described in this report appeared to be CD20"dim"+. Low ABC CD20 expression by T lymphocytic malignancies may provide a more unique immunophenotypic "fingerprint" to help support the diagnosis of T cell neoplasia vs. normal/reactive T cells (for example, low ABC CD20 cells represent only 2.4 +/- 1.5% of normal peripheral blood lymphocytes). This characteristic might also facilitate monitoring patients for residual or recurrent disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523045     DOI: 10.1002/cyto.990180206

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  9 in total

Review 1.  CD20 positive T cell lymphoma: is it a real entity?

Authors:  T Sun; A Akalin; M Rodacker; T Braun
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

Review 2.  Rituximab resistance.

Authors:  Andrew R Rezvani; David G Maloney
Journal:  Best Pract Res Clin Haematol       Date:  2011-04-13       Impact factor: 3.020

Review 3.  CD20+ T cells: an emerging T cell subset in human pathology.

Authors:  Adrian Y S Lee
Journal:  Inflamm Res       Date:  2022-08-11       Impact factor: 6.986

4.  Multispectral Imaging Approach to the Diagnosis of a CD20+ Cutaneous T-cell Lymphoproliferative Disorder: A Case Report.

Authors:  Katrin A Salva; Daniel Bennett; Jack Longley; Joan Guitart; Gary S Wood
Journal:  Am J Dermatopathol       Date:  2015-10       Impact factor: 1.533

5.  Dissection of a circulating CD3+ CD20+ T cell subpopulation in patients with psoriasis.

Authors:  J Niu; Z Zhai; F Hao; Y Zhang; Z Song; H Zhong
Journal:  Clin Exp Immunol       Date:  2018-03-06       Impact factor: 4.330

Review 6.  CD20-positive primary gastric T-cell lymphoma poorly responding to initial treatment with rituximab plus CHOP, and a literature review.

Authors:  Yasutaka Kakinoki; Junichi Hashiguchi; Takashi Ishio; Koji Chiba; Daisuke Niino; Koichi Ohshima
Journal:  Int J Hematol       Date:  2015-08-07       Impact factor: 2.490

7.  Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.

Authors:  Kwang Min Kim; Ho-Cheol Kim; Kyung-Nyeo Jeon; Hoon-Gu Kim; Jung Hun Kang; Jong Ryeal Hahm; Gyeong-Won Lee
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

8.  CD20 Positive T Cell Lymphoma Involvement of Skin.

Authors:  Ki Yeol Lee; Su Young Jeon; Jin Woo Hong; Young Hun Kim; Ki Hoon Song; Ki Ho Kim
Journal:  Ann Dermatol       Date:  2011-11-03       Impact factor: 1.444

Review 9.  CD20-positive NK/T-cell lymphoma with indolent clinical course: report of case and review of literature.

Authors:  Qing-ping Jiang; Shao-yan Liu; Yue-xin Yang; Xue-xian Tan; Juan Peng; Zhong-tang Xiong; Zhi Li
Journal:  Diagn Pathol       Date:  2012-10-02       Impact factor: 2.644

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.